These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 25817444)

  • 41. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.
    Luo J; Wang K; Yeh S; Sun Y; Liang L; Xiao Y; Xu W; Niu Y; Cheng L; Maity SN; Jiang R; Chang C
    Nat Commun; 2019 Jun; 10(1):2571. PubMed ID: 31189930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.
    Lee GT; Rosenfeld JA; Kim WT; Kwon YS; Palapattu G; Mehra R; Kim WJ; Kim IY
    PLoS One; 2019; 14(9):e0213488. PubMed ID: 31536510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
    Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
    Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug Resistance of Enzalutamide in CRPC.
    Chen X; Lu J; Xia L; Li G
    Curr Drug Targets; 2018; 19(6):613-620. PubMed ID: 28413979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
    Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H
    Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.
    Cui Y; Sun Y; Hu S; Luo J; Li L; Li X; Yeh S; Jin J; Chang C
    Oncogene; 2016 Nov; 35(47):6065-6076. PubMed ID: 27375022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
    He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
    Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.
    Patel N; Itakura T; Jeong S; Liao CP; Roy-Burman P; Zandi E; Groshen S; Pinski J; Coetzee GA; Gross ME; Fini ME
    PLoS One; 2015; 10(2):e0117758. PubMed ID: 25693195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
    Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
    Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.
    Ardiani A; Gameiro SR; Kwilas AR; Donahue RN; Hodge JW
    Oncotarget; 2014 Oct; 5(19):9335-48. PubMed ID: 25344864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of Androgen Receptor Signaling Promotes Prostate Cancer Cell Migration via Upregulation of Annexin A1 Expression.
    Yang W; Wang K; Ma J; Hui K; Lv W; Ma Z; Huan M; Luo L; Wang X; Li L; Chen Y
    Arch Med Res; 2021 Feb; 52(2):174-181. PubMed ID: 33059953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
    Wang BJ; Huang SH; Kao CL; Muller CJF; Wang YP; Chang KH; Wen HC; Yeh CC; Shih LJ; Kao YH; Huang SP; Li CY; Chuu CP
    PLoS One; 2022; 17(7):e0270803. PubMed ID: 35776912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.